OBJECTIVE: The aims of this study are to determine if outcomes of patients with ovarian carcinosarcoma (OCS) differ from women with high grade papillary serous ovarian carcinoma when compared by stage as well as to identify any associated clinico-pathologic factors. METHODS: The Surveillance, Epidemiology, and End Results (SEER) Program data for all 18 registries from 1998 to 2009 was reviewed to identify women with OCS and high grade papillary serous carcinoma of the ovary. Demographic and clinical data were compared, and the impact of tumor histology on survival was analyzed using the Kaplan-Meier method. Factors predictive of outcome were compared using the Cox proportional hazard model. RESULTS: The final study group consisted of 14,753 women. 1334 (9.04%) had OCS and 13,419 (90.96%) had high grade papillary serous carcinoma of the ovary. Overall, women with OCS had a worse five-year, disease specific survival rate, 28.2% vs. 38.4% (P<0.001). This difference persisted for each FIGO disease stages I-IV, with five year survival consistently worse for women with OCS compared with papillary serous carcinoma. Over the entire study period, after adjusting for histology, age, period of diagnosis, SEER registry, marital status, stage, surgery, radiotherapy, lymph node dissection, and history of secondary malignancy after the diagnosis of ovarian cancer, carcinosarcoma histology was associated with decreased cancer-specific survival. CONCLUSIONS: OCS is associated with a poor prognosis compared to high grade papillary serous carcinoma of the ovary. This difference was noted across all FIGO stages.
OBJECTIVE: The aims of this study are to determine if outcomes of patients with ovarian carcinosarcoma (OCS) differ from women with high grade papillary serous ovarian carcinoma when compared by stage as well as to identify any associated clinico-pathologic factors. METHODS: The Surveillance, Epidemiology, and End Results (SEER) Program data for all 18 registries from 1998 to 2009 was reviewed to identify women with OCS and high grade papillary serous carcinoma of the ovary. Demographic and clinical data were compared, and the impact of tumor histology on survival was analyzed using the Kaplan-Meier method. Factors predictive of outcome were compared using the Cox proportional hazard model. RESULTS: The final study group consisted of 14,753 women. 1334 (9.04%) had OCS and 13,419 (90.96%) had high grade papillary serous carcinoma of the ovary. Overall, women with OCS had a worse five-year, disease specific survival rate, 28.2% vs. 38.4% (P<0.001). This difference persisted for each FIGO disease stages I-IV, with five year survival consistently worse for women with OCS compared with papillary serous carcinoma. Over the entire study period, after adjusting for histology, age, period of diagnosis, SEER registry, marital status, stage, surgery, radiotherapy, lymph node dissection, and history of secondary malignancy after the diagnosis of ovarian cancer, carcinosarcoma histology was associated with decreased cancer-specific survival. CONCLUSIONS: OCS is associated with a poor prognosis compared to high grade papillary serous carcinoma of the ovary. This difference was noted across all FIGO stages.
Authors: Ibrahim Yalcin; Mehmet Mutlu Meydanli; Ahmet Taner Turan; Salih Taskin; Mustafa Erkan Sari; Tayfun Gungor; Ozgur Akbayir; Ali Ayhan Journal: Int J Clin Oncol Date: 2017-11-16 Impact factor: 3.402
Authors: Matthew A Powell; Virginia L Filiaci; Martee L Hensley; Helen Q Huang; Kathleen N Moore; Krishnansu S Tewari; Larry J Copeland; Angeles A Secord; David G Mutch; Alessandro Santin; David P Warshal; Nick M Spirtos; Paul A DiSilvestro; Olga B Ioffe; David S Miller Journal: J Clin Oncol Date: 2022-01-10 Impact factor: 50.717
Authors: Carlton L Schwab; Diana P English; Jonathan Black; Stefania Bellone; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Beatrice Bussi; Federica Predolini; Francesca Ferrari; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Peter E Schwartz; Alessandro D Santin Journal: Gynecol Oncol Date: 2015-08-08 Impact factor: 5.482
Authors: Gulden Menderes; Elena Bonazzoli; Stefania Bellone; Jonathan Black; Federica Predolini; Francesca Pettinella; Alice Masserdotti; Luca Zammataro; Gary Altwerger; Natalia Buza; Pei Hui; Serena Wong; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin Journal: Clin Cancer Res Date: 2017-07-05 Impact factor: 12.531
Authors: Marlous Hoogstraat; Mirjam S de Pagter; Geert A Cirkel; Markus J van Roosmalen; Timothy T Harkins; Karen Duran; Jennifer Kreeftmeijer; Ivo Renkens; Petronella O Witteveen; Clarence C Lee; Isaac J Nijman; Tanisha Guy; Ruben van 't Slot; Trudy N Jonges; Martijn P Lolkema; Marco J Koudijs; Ronald P Zweemer; Emile E Voest; Edwin Cuppen; Wigard P Kloosterman Journal: Genome Res Date: 2013-11-12 Impact factor: 9.043